Results 131 to 140 of about 79,419 (267)
Portal Hypertension &Cirrhosis, EarlyView.As the hepatic venous pressure gradient (HVPG) remains the current gold standard for diagnosing portal hypertension in cirrhosis, its clinical application is limited by invasiveness, high cost, and restricted availability. Given the urgent need for noninvasive techniques to dynamically monitor portal vein pressure (PVP), contrast‐enhanced ...
Danping Huang +5 more
wiley +1 more source
Incidence and Risk Factors of Chemotherapy-Induced Hepatotoxicity: A Cross-Sectional Study. [PDF]
Cancer Manag ResJoel S +16 more
europepmc +1 more source
Current Cell/Organoid and Animal Models for Primary Sclerosing Cholangitis
Portal Hypertension &Cirrhosis, EarlyView.Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease with limited therapeutic options and a marked risk of progression to biliary fibrosis, cirrhosis, and malignancy. Progress in PSC research has been hindered by the lack of models that faithfully recapitulate the complex biliary microenvironment and disease heterogeneity ...
Qigu Yao +4 more
wiley +1 more source
Traditional Chinese Medicine for lung cancer: Mechanisms, clinical evidence, and future perspectives
Precision Medical Sciences, EarlyView.Graphical abstract represents the risk factors for lung cancer, TCM efficacy and clinical outcomes to future challenges. Abstract Lung cancer remains a leading cause of global cancer mortality. Despite advances in conventional treatments such as surgery, chemotherapy, targeted therapy, and immunotherapy, challenges including drug resistance, toxicity ...
Zhangdeng Chen, Liujun Bao
wiley +1 more source
Precision Radiation Oncology, EarlyView.The dual immunomodulatory network of radiotherapy in hepatocellular carcinoma. Radiotherapy initiates its effects by inducing immunogenic cell death and DNA double‐strand breaks. Immune Activation: Cytosolic DNA from damaged cells activates the cGAS‐STING pathway, triggering IRF3/NF‐κB‐mediated type I interferon production. This enhances dendritic cell
Zhigang Fu +4 more
wiley +1 more source
Mitigating Severe Ribociclib-Hepatotoxicity With Corticosteroids. [PDF]
Case Rep Oncol MedWilliamson J +3 more
europepmc +1 more source
Ashwagandha: Is It Safe? Part 2: A Preclinical Evidence Review
Phytotherapy Research, EarlyView.ABSTRACT The preclinical evidence for the safety of ashwagandha (Withania somnifera (L.) Dunal, AS) is reviewed, and its preparations (extracts) and constituents, from the general toxicity in animal models to in vitro and cell culture studies, which may elucidate mechanisms of action and explain clinical case reports.
Elizabeth M. Williamson, Thomas Brendler
wiley +1 more source
Ashwagandha: Is It Safe? Part 1: A Regulatory Review
Phytotherapy Research, EarlyView.ABSTRACT Over the last decade, ashwagandha (Withania somnifera (L.) Dunal, AS) has been brought under increasing scrutiny by EU regulators regarding its safety for the use in food supplements, culminating in a recent recommendation for an Article 8 procedure according to Regulation (EC) No. 1925/2006 in the European Union (EU).
T. Brendler +5 more
wiley +1 more source
Development and Validation of the TCAP Nomogram for Predicting Hepatotoxicity Risk in Hepatocellular Carcinoma Patients Receiving TACE Combined with Systemic Therapy. [PDF]
J Hepatocell CarcinomaMa S, Shi C, Chen J, Song J, Li J.
europepmc +1 more source
Safety Evaluation of an Aqueous Root and Leaf Extract of Ashwagandha (Withania somnifera)
Phytotherapy Research, EarlyView.Sensoril, an aqueous root and leaf extract of ashwagandha showed no evidence of mutagenicity in the in vitro Ames assay, was negative in the in vitro micronucleus, in vivo mammalian bone marrow chromosome aberration assays, and was well tolerated in the rat at up to 4000 mg/kg BW/day when administered orally for a period of 90 days. The data from these
Mukesh Summan +2 more
wiley +1 more source